Usefulness of serum fibrinogen degradation product-E in sporadic cases of classical hemolytic uremic syndrome

被引:3
作者
Aihara, Y [1 ]
Nakamura, T [1 ]
Unayama, T [1 ]
Yoshida, Y [1 ]
Yokota, S [1 ]
机构
[1] Yokohama City Univ, Med Ctr, Dept Pediat, Minami Ku, Yokohama, Kanagawa 2320024, Japan
关键词
fibrin/fibrinogen degradation product-E fraction; hemolytic uremic syndrome; marker; Shiga toxin-producing Escherichia coli O15 : H7;
D O I
10.1046/j.1442-200x.2000.01266.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Hemolytic uremic syndrome (HUS) associated with Shiga toxin (Stx)-producing Escherichia coli O157:H7 infection is one of the diseases causing acute renal failure in young children. Although HUS is still a serious disease in children, no reliable predictive markers for HUS nor markers of disease severity are available so far. Recently, we experienced a sporadic case of typical HUS caused by Stx-producing E. coli O157:H7 and detected, at the prodromal stage, a high level of serum fibrin/fibrinogen degradation product-E (FDP-E) fraction. Methods: To assess the usefulness of FDP-E for the treatment of HUS in clinical practice, we retrospectively examined serum levels of FDP-E in 22 patients with bloody diarrhea with or without HUS. Results: There were significantly increased levels of serum FDP-E in patients with HUS, but not in those without HUS. Furthermore, serum levels of FDP-E may correlate with disease severity in patients with HUS. Conclusions: These results suggest that serum levels of FDP-E may be a useful marker of HUS in clinical practice.
引用
收藏
页码:523 / 527
页数:5
相关论文
共 13 条
[1]  
Aihara Y, 1997, PEDIATR NEPHROL, V11, P389
[2]  
AOKI N, 1988, REVISED DIAGNOSTIC C
[3]   ENZYME-LINKED IMMUNOSORBENT ASSAYS FOR DETECTING ANTIBODIES TO SHIGA-LIKE TOXIN-I, SHIGA-LIKE TOXIN-II, AND ESCHERICHIA-COLI O157-H7 LIPOPOLYSACCHARIDE IN HUMAN SERUM [J].
BARRETT, TJ ;
GREEN, JH ;
GRIFFIN, PM ;
PAVIA, AT ;
OSTROFF, SM ;
WACHSMUTH, IK .
CURRENT MICROBIOLOGY, 1991, 23 (04) :189-195
[4]   CURRENT CONCEPTS - ESCHERICHIA-COLI O157-H7 AND THE HEMOLYTIC-UREMIC SYNDROME [J].
BOYCE, TG ;
SWERDLOW, DL ;
GRIFFIN, PM .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (06) :364-368
[5]  
Calderwood SB, 1996, ASM NEWS, V62, P118
[6]  
INAMO Y, 1995, BRIT J RHEUMATOL, V34, P466
[7]  
JACKSON MP, 1987, FEMS MICROBIOL LETT, V44, P109, DOI 10.1111/j.1574-6968.1987.tb02252.x
[8]   RECENT ADVANCES IN UNDERSTANDING THE PATHOGENESIS OF THE HEMOLYTIC UREMIC SYNDROMES [J].
KAPLAN, BS ;
CLEARY, TG ;
OBRIG, TG .
PEDIATRIC NEPHROLOGY, 1990, 4 (03) :276-283
[9]   SPORADIC CASES OF HEMOLYTIC-UREMIC SYNDROME ASSOCIATED WITH FECAL CYTO-TOXIN AND CYTOTOXIN-PRODUCING ESCHERICHIA-COLI IN STOOLS [J].
KARMALI, MA ;
PETRIC, M ;
STEELE, BT ;
LIM, C .
LANCET, 1983, 1 (8325) :619-620
[10]   Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura [J].
Karpman, D ;
Andreasson, A ;
Thysell, H ;
Kaplan, BS ;
Svanborg, C .
PEDIATRIC NEPHROLOGY, 1995, 9 (06) :694-699